Biotechnology News and Research

RSS

Vitrolife and Cellartis extend collaboration in stem cell research

Vitrolife has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.

8 Oct 2009

Susquehanna Health acquires a Daxor blood volume analyzer

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Susquehanna Health of Williamsport, Pennsylvania. This will provide Susquehanna Health with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

Odyssey Thera to receive milestone payments from Pfizer

Odyssey Thera, Inc. announced that it will receive milestone payments from one of its investors, Pfizer Inc. following Pfizer's decision to progress drug candidates studied by Odyssey Thera as part of Odyssey's multi-year alliance with Pfizer announced in August, 2006.

7 Oct 2009

DBMS Consulting completes deployment of OHSA Suite and EBS for SIRO Clinpharm

DBMS Consulting announced that it has successfully completed deployment of Oracle Life Sciences Applications (OHSA) Suite and Oracle E-Business Suite (EBS) for SIRO Clinpharm, one of the leading global CROs headquartered in Thane, India. OHSA offers fully automated capabilities in management of clinical trial process, clinical trial data and global adverse event reporting.

7 Oct 2009

Tranziger forms global advisory and business team to execute strategic transactions

Tranziger Limited announced today the formation of its global advisory and business team to advise and assess companies in the life sciences and healthcare sectors to execute strategic transactions and realise and optimise value from their portfolios in these turbulent times. Tranziger Limited is headquartered in London, England, UK and has offices in Washington, DC and Edinburgh.

7 Oct 2009

Roche and Genentech obtain license to use SurModics’ drug delivery system

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has signed a License and Development Agreement with Roche and Genentech, Inc., a wholly-owned member of the Roche Group.

7 Oct 2009

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

7 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

German research institutes and companies to introduce their activities at WEFTEC.09

As part of the initiative "Research in Germany - Land of Ideas", German research institutes, universities and companies will introduce themselves and their activities at this year's WEFTEC.09.

7 Oct 2009

FDA reviews Fibrocell Science's BLA for azfibrocel-T

Isolagen, Inc. has reorganized and emerged from bankruptcy as Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on developing regenerative fibroblast cells for aesthetic, medical and scientific applications.

7 Oct 2009

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage.

7 Oct 2009

Guidelines for implementing spirituality for improved healthcare

Guidelines derived from a recent Consensus Conference, including recommendations on the role of healthcare providers in the assurance of quality spiritual care to patients in a palliative care setting, are published in a comprehensive report in Journal of Palliative Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc. (www.liebertpub.com).

7 Oct 2009

FDA provides Genzyme a complete response letter for Clolar NDA

Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.

7 Oct 2009

FDA completes inspection of Catalent Pharma's manufacturing facility in Germany

Catalent Pharma Solutions announces that its integrated dose form development, manufacturing and packaging facility in Schorndorf, Germany, has successfully completed an FDA inspection.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

HSCI declares preliminary price range for its initial public offering

Joint Stock Company Human Stem Cell Institute” (“HSCI” or “the Company”), Russia’s leader in stem cell technology, today announced the preliminary price range for its initial public offering (“IPO”).

7 Oct 2009

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

BioReliance Corporation announced today that it has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological therapeutics and other biologically based products the ability to detect this potential contaminant of mammalian cell culture based systems.

7 Oct 2009

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc., today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from a study of Vicor's PD2i VS™ (Vital Sign) at the American Heart Association's Resuscitation Science Symposium 2009 on November 14-15, 2009 in Orlando, Florida.

7 Oct 2009

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Business Day examines efforts currently underway in Africa to bolster the continent's ability to develop new drugs and diagnostics.

7 Oct 2009

Biotechnology News and Research

Vitrolife and Cellartis extend collaboration in stem cell research

Susquehanna Health acquires a Daxor blood volume analyzer

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Odyssey Thera to receive milestone payments from Pfizer

DBMS Consulting completes deployment of OHSA Suite and EBS for SIRO Clinpharm

Tranziger forms global advisory and business team to execute strategic transactions

Roche and Genentech obtain license to use SurModics’ drug delivery system

Nutra Pharma to launch prescription analgesic for severe chronic pain treatment

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

German research institutes and companies to introduce their activities at WEFTEC.09

FDA reviews Fibrocell Science's BLA for azfibrocel-T

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

Guidelines for implementing spirituality for improved healthcare

FDA provides Genzyme a complete response letter for Clolar NDA

FDA completes inspection of Catalent Pharma's manufacturing facility in Germany

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

HSCI declares preliminary price range for its initial public offering

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Biotechnology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News